High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 9, 2015, Pages 1687-1699

  Petrov, Dmitry ^a,c   Pedrós, Ignacio ^b,c   Artiach, Gonzalo ^a,c   Sureda, Francesc X ^b,c   Barroso, Emma ^a,d   Pallàs, Mercè ^a,c   Casadesús, Gemma ^e   Beas Zarate, Carlos ^f,g   Carro, Eva ^h   Ferrer, Isidro ⁱ   Vazquez Carrera, Manuel ^a,d   Folch, Jaume ^b,c   Camins, Antoni ^a,c,j  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e KENT STATE UNIVERSITY   (United States)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^g CUCBA   (Mexico)

^h Universidad Complutense   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j UNIVERSIDAD NACIONAL DE LOJA   (Ecuador)

more..

Author keywords

Alzheimer disease; APPSwe PS1dE9; Hippocampus; Insulin receptor; Mitochondria; TAU

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLESTEROL; CYCLIN DEPENDENT KINASE 5; ESTROGEN RELATED RECEPTOR ALPHA; GA BINDING PROTEIN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREPROINSULIN; PROTEIN KINASE B; PROTEIN P35; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1; TAU PROTEIN; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BRAIN METABOLISM; BRAIN MITOCHONDRION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HOMEOSTASIS; HYPERINSULINEMIA; IMMUNOBLOTTING; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; MALE; MEMORY; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN;

ANIMALIA; MUS; RODENTIA;

EID: 84930679125     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.05.004     Document Type: Article

References (74)

1. Traill W.B., Mazzocchi M., Shankar B., Hallam D. Importance of government policies and other influences in transforming global diets. Nutr. Rev. 2014, 72:591-604. 10.1111/nure.12134.
2. Finkelstein E.a, Brown D.S., Wrage L.a, Allaire B.T., Hoerger T.J. Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity 2010, 18:333-339. 10.1038/oby.2009.253.
3. Field a E., Coakley E.H., Must a, Spadano J.L., Laird N., Dietz W.H., et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 2001, 161:1581-1586.
4. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kåreholt I., Winblad B., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005, 62:1556-1560. 10.1001/archneur.62.10.1556.
5. Beydoun M.A., Beydoun H.A., Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev. 2008, 9:204-218. 10.1111/j.1467-789X.2008.00473.x.
6. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O'Meara E.S., Longstreth W.T., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66:336-342. 10.1001/archneurol.2008.582.
7. Nepal B., Brown L.J., Anstey K.J. Rising midlife obesity will worsen future prevalence of dementia. PLoS One 2014, 9:e99305. 10.1371/journal.pone.0099305.
8. Barnes D.E., Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011, 10:819-828. 10.1016/S1474-4422(11)70072-2.
9. Norton S., Matthews F.E., Barnes D.E., Yaffe K., Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014, 13:819-828. 10.1016/S1474-4422(11)70072-2.
10. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
11. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
12. Ferreira S.T., Klein W.L. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 2011, 96:529-543. 10.1016/j.nlm.2011.08.003.
13. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
14. Zhu X., Perry G., Smith M.a Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J. Alzheimers Dis. 2005, 7:81-84.
15. de la Monte S.M., Wands J.R. Alzheimer's disease is type 3 diabetes - evidence reviewed. J. Diabetes Sci. Technol. 2008, 2:1101-1113. 10.1177/193229680800200619.
16. Hokama M., Oka S., Leon J., Ninomiya T., Honda H., Sasaki K., et al. Altered expression of diabetes-related genes in Alzheimer's disease brains: the hisayama study. Cereb. Cortex 2014, 24:2476-2488. 10.1093/cercor/bht101.
17. Johnson G.V.W. Tau phosphorylation and proteolysis: insights and perspectives. J. Alzheimers Dis. 2006, 9:243-250.
18. Kim B., Backus C., Oh S., Hayes J.M., Feldman E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150:5294-5301. 10.1210/en.2009-0695.
19. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219. 10.3233/JAD-2010-1314.
20. White M.F. IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes. Metab. 2014, 16(Suppl. 1):4-15. 10.1111/dom.12347.
21. Gold S.M., Dziobek I., Sweat V., Tirsi a., Rogers K., Bruehl H., et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50:711-719. 10.1007/s00125-007-0602-7.
22. Bruehl H., Wolf O.T., Sweat V., Tirsi A., Richardson S., Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 2009, 1280:186-194. 10.1016/j.brainres.2009.05.032.
23. Wang X., Zheng W., Xie J.-W., Wang T., Wang S.-L., Teng W.-P., et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol. Neurodegener. 2010, 5:46. 10.1186/1750-1326-5-46.
24. Ravona-Springer R., Moshier E., Schmeidler J., Godbold J., Akrivos J., Rapp M., et al. Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J. Alzheimers Dis. 2012, 30:299-309. 10.3233/JAD-2012-120106.
25. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 2004, 490:115-125. 10.1016/j.ejphar.2004.02.049.
26. Femminella G.D., Edison P. Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimers Dement. 2014, 10:S55-S61. 10.1016/j.jalz.2013.12.012.
27. McNay E.C., Recknagel A.K. Reprint of: "Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes,". Neurobiol. Learn. Mem. 2011, 96:517-528. 10.1016/j.nlm.2011.11.001.
28. Hölscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer ' s and Parkinson ' s diseases. Acta Phys. Sin. 2014, 66:497-510. 10.13294/j.aps.2014.0059.
29. Castro G., Areias M.F.C., Weissmann L., Quaresma P.G.F., Katashima C.K., Saad M.J.a, et al. Diet-induced obesity induces endoplasmic reticulum stress and insulin resistance in the amygdala of rats. FEBS Open Bio 2013, 3:443-449. 10.1016/j.fob.2013.09.002.
30. Oh H., Boghossian S., York D.a, Park-York M. The effect of high fat diet and saturated fatty acids on insulin signaling in the amygdala and hypothalamus of rats. Brain Res. 2013, 1537:191-200. 10.1016/j.brainres.2013.09.025.
31. Arnold S.E., Lucki I., Brookshire B.R., Carlson G.C., Browne C.a, Kazi H., et al. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol. Dis. 2014, 67:79-87. 10.1016/j.nbd.2014.03.011.
32. Ayala J.E., Samuel V.T., Morton G.J., Obici S., Croniger C.M., Shulman G.I., et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model. Mech. 2010, 3:525-534. 10.1242/dmm.006239.
33. Pedrós I., Petrov D., Allgaier M., Sureda F., Barroso E., Beas-Zarate C., et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:1556-1566. 10.1016/j.bbadis.2014.05.025.
34. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159. 10.1006/abio.1987.9999.
35. Porquet D., Griñán-Ferré C., Ferrer I., Camins A., Sanfeliu C., Del Valle J., et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease. J. Alzheimers Dis. 2014, 42:1209-1220. 10.3233/JAD-140444.
36. Schneider L.S., Mangialasche F., Andreasen N., Feldman H., Giacobini E., Jones R., et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J. Intern. Med. 2014, 275:251-283. 10.1111/joim.12191.
37. Karran E., Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 2014, 76:185-205. 10.1002/ana.24188.
38. Schapira A.H. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol. 1996, 9:260-264.
39. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 1997, 174:193-197.
40. Mattson M.P. Mother's legacy: mitochondrial DNA mutations and Alzheimer's disease. Trends Neurosci. 1997, 20:373-375.
41. Swerdlow R.H., Khan S.M. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63:8-20. 10.1016/j.mehy.2003.12.045.
42. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20(Suppl. 2):S265-S279. 10.3233/JAD-2010-100339.
43. Swerdlow R.H. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal. 2012, 16:1434-1455. 10.1089/ars.2011.4149.
44. Selfridge J.E., Lezi E., Lu J., Swerdlow R.H. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol. Dis. 2013, 51:3-12. 10.1016/j.nbd.2011.12.057.
45. Demetrius L.a, Driver J. Alzheimer's as a metabolic disease. Biogerontology 2013, 14:641-649. 10.1007/s10522-013-9479-7.
46. Ramos-Rodriguez J.J., Ortiz-Barajas O., Gamero-Carrasco C., de la Rosa P.R., Infante-Garcia C., Zopeque-Garcia N., et al. Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology 2014, 48:123-135. 10.1016/j.psyneuen.2014.06.005.
47. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
48. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 2013, 123:531-539. 10.1172/JCI64595.
49. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272. 10.2337/db13-1954.
50. Takeda S., Sato N., Rakugi H., Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol. BioSyst. 2011, 7:1822-1827. 10.1039/c0mb00302f.
51. Boitard C., Etchamendy N., Sauvant J., Aubert A., Tronel S., Marighetto A., et al. Juvenile, but not adult exposure to high-fat diet impairs relational memory and hippocampal neurogenesis in mice. Hippocampus 2012, 22:2095-2100. 10.1002/hipo.22032.
52. Kaiyala K.J., Prigeon R.L., Kahn S.E., Woods S.C., Schwartz M.W. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000, 49:1525-1533.
53. Begg D.P., Mul J.D., Liu M., Reedy B.M., D'Alessio D.a, Seeley R.J., et al. Reversal of diet-induced obesity increases insulin transport into cerebrospinal fluid and restores sensitivity to the anorexic action of central insulin in male rats. Endocrinology 2013, 154:1047-1054. 10.1210/en.2012-1929.
54. Heni M., Schöpfer P., Peter A., Sartorius T., Fritsche A., Synofzik M., et al. Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. Acta Diabetol. 2014, 51:679-681. 10.1007/s00592-013-0546-y.
55. Kanoski S.E., Davidson T.L. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol. Behav. 2011, 103:59-68. 10.1016/j.physbeh.2010.12.003.
56. Banks W.a, Owen J.B., Erickson M.a Insulin in the brain: there and back again. Pharmacol. Ther. 2012, 136:82-93. 10.1016/j.pharmthera.2012.07.006.
57. Copps K.D., White M.F. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012, 55:2565-2582. 10.1007/s00125-012-2644-8.
58. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 2000, 106:165-169. 10.1172/JCI10582.
59. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243. 10.1016/j.neurobiolaging.2008.04.002.
60. Grote C.W., Morris J.K., Ryals J.M., Geiger P.C., Wright D.E. Insulin receptor substrate 2 expression and involvement in neuronal insulin resistance in diabetic neuropathy. Exp. Diabetes Res. 2011, 2011:212571. 10.1155/2011/212571.
61. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:309-317.
62. Sarbassov D.D., Guertin D.a, Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148.
63. Cole A., Frame S., Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 2004, 377:249-255. 10.1042/BJ20031259.
64. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.-X. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011, 225:54-62. 10.1002/path.2912.
65. Dineley K.T., Jahrling J.B., Denner L. Insulin resistance in Alzheimer's disease. Neurobiol. Dis. 2014, 72:92-103. 10.1016/j.nbd.2014.09.001.
66. Ronnett G.V., Ramamurthy S., Kleman A.M., Landree L.E., Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 2009, 109:17-23. (Suppl.). 10.1111/j.1471-4159.2009.05916.x.
67. Jahrling J.B., Hernandez C.M., Denner L., Dineley K.T. PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. J. Neurosci. 2014, 34:4054-4063. 10.1523/JNEUROSCI.4024-13.2014.
68. Feld M., Krawczyk M.C., Sol Fustiñana M., Blake M.G., Baratti C.M., Romano A., et al. Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2014, 40:69-82. 10.3233/JAD-131076.
69. Chami L., Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol. Neurodegener. 2012, 7:52. 10.1186/1750-1326-7-52.
70. Sabio G., Davis R.J. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends Biochem. Sci. 2010, 35:490-496. 10.1016/j.tibs.2010.04.004.
71. Desai G.S., Zheng C., Geetha T., Mathews S.T., White B.D., Huggins K.W., et al. The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. J. Alzheimers Dis. 2014, 42:347-356. 10.3233/JAD-140018.
72. Austin S., St-Pierre J. PGC1α and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J. Cell Sci. 2012, 125:4963-4971. 10.1242/jcs.113662.
73. Eckert A., Schulz K.L., Rhein V., Götz J. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol. Neurobiol. 2010, 41:107-114. 10.1007/s12035-010-8109-5.
74. Grillo C.a, Piroli G.G., Hendry R.M., Reagan L.P. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009, 1296:35-45. 10.1016/j.brainres.2009.08.005.